Advertisement

Adeno-Associated Viral-Mediated Gene Therapy of Lysosomal Storage Disorders

  • Mario A. Cabrera-Salazar
  • Seng H. Cheng

Lysosomal storage disorders (LSD) are a group of inherited diseases that result as a consequence of the loss of one or more of the several lysosomal enzymes that are responsible for the catabolism of a variety of macromolecules. The LSD as a group, present with an incidence of approximately 1 in 7500 live births making it one of the more prevalent groups of genetic diseases. The description of the pathophysiology of LSD, as well as their biochemical basis has facilitated the development of several therapeutic approaches for the treatment of this group of disorders. These include the use of enzyme replacement (see Chapter 3, this book), substrate inhibition (see Chapter 11, this book), and cell and gene-based therapies (see Chapter 14, this book). Enzyme and of these diseases. However, for a large number of the LSD, especially those affecting small molecule therapies have been successfully developed for a small number the central nervous system, no therapies are available as yet. Moreover, improvements to the current treatments are desirable and are under active consideration by a number of investigators. This review focuses specifically on the potential of gene therapy and in particular the use of recombinant adeno-associated viral (AAV) vectors as an alternate approach to treat the visceral and CNS manifestations shown associated with these enzymatic deficiencies.

Keywords

Lysosomal Enzyme Fabry Disease Pompe Disease Lysosomal Storage Disorder AAV2 Vector 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Atchison RW, Casto BC, Hammon WM., 1965, Adenovirus associated defective virus particles. Science 49:754.CrossRefGoogle Scholar
  2. Barbon CM, Ziegler RJ, Li C, Armentano D, Cherry M, Desnick RJ, Schuchman EH, Cheng SH., 2005, AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease. Mol Ther. 3:431.CrossRefGoogle Scholar
  3. Barranger JA., 1984, Marrow transplantation in genetic disease. N Engl J Med. 311:1629.PubMedCrossRefGoogle Scholar
  4. Bessis N, Garcia-Cozar FJ, Boissier MC., 2004, Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. Suppl 1:S10-7.Google Scholar
  5. Blankinship MJ, Gregorevic P, Chamberlain JS., 2006, Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Mol Ther. 2:241-9.CrossRefGoogle Scholar
  6. Bona C., 2005, Effect of maternal antibodies on neonatal B cell response. In Bona C (Ed.) Neonatal Immunity. Totowa, NJ: Humana Press, 159-178.CrossRefGoogle Scholar
  7. Burguete T, Rabreau M, Fontanges-Darriet M, Roset E, Hager HD, Koppel A, Bischof P, Schlehofer JR., 1999, Evidence for infection of the human embryo with adeno-associated virus in pregnancy. Hum Reprod. 14:2396.CrossRefPubMedGoogle Scholar
  8. Carter BJ., 2005, Adeno-associated virus vectors in clinical trials. Hum Gene Ther. 16:541.CrossRefPubMedGoogle Scholar
  9. Carter BJ, Burstein H, Peluso RW., 2004, Adeno-associated virus and AAV vectors for gene delivery. In: Templeton NS (Ed.) Gene and Cell Therapy Therapeutic Mecha-nisms and Strategies, second edition. Switzerland: Marcel Dekker, pp. 71-101.Google Scholar
  10. Cressant A, Desmaris N, Verot L, Brejot T, Froissart R, Vanier MT, Maire I, Heard JM., 2004, Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci. 24:10229.CrossRefPubMedGoogle Scholar
  11. Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, Stieg P, Souweidane M, Hosain S, Heier L, Ballon D, Dinner M, Wisniewski K, Kaplitt M, Greenwald BM, Howell JD, Strybing K, Dyke J, Voss H., 2004, Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther. 15:1131.PubMedGoogle Scholar
  12. Daly TM, Ohlemiller KK, Roberts MS, Vogler CA, Sands MS., 2001, Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther. 8:1291.CrossRefPubMedGoogle Scholar
  13. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA., 2000, Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA. 97:3428.CrossRefPubMedGoogle Scholar
  14. Ding E, Hu H, Hodges BL, Migone F, Serra D, Xu F, Chen YT, Amalfitano A., 2002, Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther. 5:436.CrossRefPubMedGoogle Scholar
  15. Dodge JC, Clarke J, Song A, Bu J, Yang W, Taksir TV, Griffiths D, Zhao MA, Schuchman EH, Cheng SH, O’Riordan CR, Shihabuddin LS, Passini MA, Stewart GR., 2005, Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc Natl Acad  ci USA. 102:17822.CrossRefGoogle Scholar
  16. Ellinwood NM, Vite CH, Haskins ME., 2004, Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med. 6:481.CrossRefPubMedGoogle Scholar
  17. Erles K, Sebokova P, Schlehofer JR., 1999, Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 59:406.CrossRefPubMedGoogle Scholar
  18. Fraites TJ Jr, Schleissing MR, Shanely RA, Walter GA, Cloutier DA, Zolotukhin I, Pauly DF, Raben N, Plotz PH, Powers SK, Kessler PD, Byrne BJ., 2002, Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther. 5:571.CrossRefPubMedGoogle Scholar
  19. Franco LM, Sun B, Yang X, Bird A, Zhang H, Schneider A, Brown T, Young SP, Clay TM, Amalfitano A, Chen YT, Koeberl DD., 2005, Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease Type II. Mol Ther. 12:876.CrossRefPubMedGoogle Scholar
  20. Fratantoni JC, Hall CW, Neufeld EF., 1968, Hurler and Hunter syndromes: Mutual correction of the defect in cultured fibroblasts. Science 162:570-2.CrossRefPubMedGoogle Scholar
  21. Fu H, Samulski RJ, McCown TJ, Picornell YJ, Fletcher D, Muenzer J., 2002, Neuro-logical correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adenoassociated virus-mediated gene delivery. Mol Ther. 5:42.CrossRefPubMedGoogle Scholar
  22. Furbish FS, Steer CJ, Barranger JA, Jones EA, Brady RO., 1978, The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells. Biochem Biophys Res Commun. 8:1047.CrossRefGoogle Scholar
  23. Fuxe K, Tinner B, Chadi G, Harfstrand A, Agnati LF., 1994, Evidence for a regional distribution of hyaluronic acid in the rat brain using a highly specific hyaluronic acid recognizing protein. Neurosci Lett. 169:25.CrossRefPubMedGoogle Scholar
  24. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM., 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA. 99:11854.CrossRefPubMedGoogle Scholar
  25. Hartung SD, Frandsen JL, Pan D, Koniar BL, Graupman P, Gunther R, Low WC, Whitley CB, McIvor RS., 2004, Correction of metabolic, craniofacial, and neurologic abnor-malities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther. 9:866.CrossRefPubMedGoogle Scholar
  26. Haskell RE, Hughes SM, Chiorini JA, Alisky JM, Davidson BL., 2003, Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system. Gene Ther. 10:34.CrossRefPubMedGoogle Scholar
  27. Hennig AK, Ogilvie JM, Ohlemiller KK, Timmers AM, Hauswirth WW, Sands MS., 2004, AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice. Mol Ther. 10:106.CrossRefPubMedGoogle Scholar
  28. Hickman S, Shapiro LJ, Neufeld EF., 1974, A recognition marker required for uptake of a lysosomal enzyme by cultured fibroblasts. Biochem Biophys Res Commun. 57:55.CrossRefPubMedGoogle Scholar
  29. Hoggan MD, Blackow NR, Rowe WP., 1966, Studies of small DNA viruses found in different adenovirus preparations: Physical biological and immunological characteristics. Proc Natl Acad Sci USA. 55:1467.CrossRefPubMedGoogle Scholar
  30. Jung SC, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P., 2001, Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA. 98:2676.CrossRefPubMedGoogle Scholar
  31. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O’Malley KL, During MJ., 1994, Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet. 8:148.CrossRefPubMedGoogle Scholar
  32. Kaspar BK, Erickson D, Schaffer D, Hinh L, Gage FH, Peterson DA., 2002, Targeted retrograde gene delivery for neuronal protection. Mol Ther. 5:50.CrossRefPubMedGoogle Scholar
  33. Kitada K, Akimitsu T, Shigematsu Y, Kondo A, Maihara T, Yokoi N, Kuramoto T. Sasa M, Serikawa T., 2000, Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system. J Neurochem. 74:2512.CrossRefPubMedGoogle Scholar
  34. Leone P, Janson CG, Bilaniuk L, Wang Z, Sorgi F, Huang L, Matalon R, Kaul R, Zeng Z, Freese A, McPhee SW, Mee E, During MJ., 2000, Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol. 48:27.CrossRefPubMedGoogle Scholar
  35. Loeb JE, Cordier WS, Harris ME, Weitzman MD, Hope TJ., 1999, Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther. 10:2295.CrossRefPubMedGoogle Scholar
  36. Martin-Touaux E, Puech JP, Chateau D, Emiliani C, Kremer EJ, Raben N, Tancini B, Orlacchio A, Kahn A, Poenaru L., 2002, Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy. Hum Mol Genet. 11:1637.CrossRefPubMedGoogle Scholar
  37. McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ., 1996, Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713:99.CrossRefPubMedGoogle Scholar
  38. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG, Patel SD., 2000, Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol. 74:1761.CrossRefPubMedGoogle Scholar
  39. Passini MA, Dodge JC, Bu J, Yang W, Zhao Q, Sondhi D, Hackett N, Kaminsky S, Mao Q, Shihabuddin LS, Cheng SH, Sleat D, Stewart GR, Lobel P, Crystal RG., 2006, Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J Neurosci. 26:1334.CrossRefPubMedGoogle Scholar
  40. Passini MA, Macauley SL, Huff MR, Taksir TV, Bu J, Wu IH, Piepenhagen PA, Dodge JC, Shihabuddin LS, O’Riordan CR, Schuchman EH, Stewart GR., 2005, AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol Ther. 11:754.CrossRefPubMedGoogle Scholar
  41. Passini MA, Watson DJ, Vite CH, Landsburg DJ, Feigenbaum AL, Wolfe JH., 2003, Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J Virol. 77:7034.CrossRefPubMedGoogle Scholar
  42. Passini MA, Wolfe JH., 2001, Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector. J Virol. 75:12382.CrossRefPubMedGoogle Scholar
  43. Paterna JC, Moccetti T, Mura A, Feldon J, Bueler H., 2000, Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expre-ssion in the rat brain. Gene Ther. 7:1304.CrossRefPubMedGoogle Scholar
  44. Qiao C, Li J, Zhu T, Draviam R, Watkins S, Ye X, Chen C, Li J, Xiao X., 2005, Amelioration of laminin-{alpha}2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc Natl Acad Sci USA. 102:11999.CrossRefPubMedGoogle Scholar
  45. Raben N, Lu N, Nagaraju K, Rivera Y, Lee A, Yan B, Byrne B, Meikle PJ, Umapathysivam K, Hopwood JJ, Plotz PH., 2001, Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: Implications for therapy. Hum Mol Genet. 10:2039.CrossRefPubMedGoogle Scholar
  46. Rafi MA, Zhi Rao H, Passini MA, Curtis M, Vanier MT, Zaka M, Luzi P, Wolfe JH, Wenger DA., 2005, AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy. Mol Ther. 11:734.CrossRefPubMedGoogle Scholar
  47. Sondhi D, Peterson DA, Giannaris EL, Sanders CT, Mendez BS, De B, Rostkowski AB, Blanchard B, Bjugstad K, Sladek JR Jr, Redmond DE Jr, Leopold PL, Kaminsky SM, Hackett NR, Crystal RG., 2005, AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther. 12:1618.CrossRefPubMedGoogle Scholar
  48. Summerford C, Samulski RJ., 1988, Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 72:1438.Google Scholar
  49. Takahashi H, Hirai Y, Migita M, Seino Y, Fukuda Y, Sakuraba H, Kase R, Kobayashi T, Hashimoto Y, Shimada T., 2002, Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci USA. 99:13777CrossRefPubMedGoogle Scholar
  50. Tenenbaum L, Jurysta F, Stathopoulos A, Puschban Z, Melas C, Hermens WT, Verhaagen J, Pichon B, Velu T, Levivier M., 2000, Tropism of AAV-2 vectors for neurons of the globus pallidus. Neuroreport. 11:2277.CrossRefPubMedGoogle Scholar
  51. Wadsworth SC, Cheng SH., 2004, AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther. 9:231.PubMedGoogle Scholar
  52. Walz C, Deprez A, Dupressoir T, Durst M, Rabreau M, Schlehofer JR. 1997, Interaction of human papillomavirus type 16 and adeno-associated virus type 2 co-infecting human cervical epithelium. J Gen Virol. 78:1441.PubMedGoogle Scholar
  53. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM., 2000, Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther. 1:154.CrossRefPubMedGoogle Scholar
  54. Xu R, Janson CG, Mastakov M, Lawlor P, Young D, Mouravlev A, Fitzsimons H, Choi KL, Ma H, Dragunow M, Leone P, Chen Q, Dicker B, During MJ., 2001, Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther. 8:1323.CrossRefPubMedGoogle Scholar
  55. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA., 2002, Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol. 76:4580.CrossRefPubMedGoogle Scholar
  56. Zhang Y, Chirmule N, Gao G, Wilson J., 2000, CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: Role of immature dendritic cells. J Virol. 74:8003.CrossRefPubMedGoogle Scholar
  57. Ziegler RJ, Lonning SM, Armentano D, Li C, Souza DW, Cherry M, Ford C, Barbon CM, Desnick RJ, Gao G, Wilson JM, Peluso R, Godwin S, Carter BJ, Gregory RJ, Wadsworth SC, Cheng SH., 2004, AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther. 9:231-40.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Mario A. Cabrera-Salazar
    • 1
  • Seng H. Cheng
    • 1
  1. 1.Genetic Diseases ScienceGenzyme CorporationFraminghamUSA

Personalised recommendations